Has Richard Cheng, MD received payments from drug or device companies?

Yes. Drug and device makers reported $759 in general payments to Richard Cheng, MD across 10 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Richard Cheng, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Richard Cheng, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Richard Cheng, MD

Advanced Heart Failure and Transplant Cardiology · Seattle, WANPI 1548423502

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 10 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 4 manufacturers reported payments, led by Abbott at 42.8% of the total. That places this record below the midpoint for advanced heart failure and transplant cardiology clinicians in WA, where the typical reported total is $3,028.

$759in general payments, 2019–2025

Across 10 payments — averaging $75.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Abbott$325
Abiomed$248
Medtronic$97
Ancora Heart, Inc.$89

$269,256in research payments, 2019–2025

Across 27 payments — averaging $9972.44 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

AstraZeneca$142K
Ionis Pharmaceuticals, Inc.$109K
Eidos Therapeutics, Inc.$13K
Astrazeneca UK Limited$5K

What the payments were for

Food & beverage$759100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Abbott	6	$325
Abiomed	2	$248
Medtronic	1	$97
Ancora Heart, Inc.	1	$89

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Impella$248
THORATEC HEARTMATE 3 LVAS IMPLANT KIT$111

How this compares

$759 in reported general payments places this provider in the 25th percentile of 20 advanced heart failure and transplant cardiology providers in Washington.

See all advanced heart failure and transplant cardiology providers in Washington →

Medicare billing

Part B allowed, 2024

$79,237

Medicare patients

546

Services billed

1,170

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
VyndamaxTafamidis	401	$11,333,900
VyndaqelTafamidis Meglumine	13	$470,115
EliquisApixaban	149	$197,501
JardianceEmpagliflozin	133	$182,512
EntrestoSacubitril/Valsartan	83	$133,299
XareltoRivaroxaban	31	$41,284
FarxigaDapagliflozin Propanediol	30	$38,470
Sirolimus	56	$26,224
Tacrolimus	145	$11,717
Dapsone	42	$4,996
Mycophenolate Mofetil	43	$4,828
Eplerenone	21	$3,370
Potassium Chloride	73	$2,407
Metoprolol Succinate	138	$2,131
Torsemide	53	$1,566

Paid to pharmacies, not to this prescriber.

Other advanced heart failure and transplant cardiology in Seattle

Wayne LevySeattle$275K
John MignoneSeattle$19K
Preethi PirlamarlaSeattle$14K
Salpy PamboukianSeattle$5K
James ZhangSeattle$3K
April Stempien OteroSeattle$2K
Sunu ThomasSeattle$2K
Elina MinamiSeattle$698
Daniel FishbeinSeattle$600
Kevin ObrienSeattle$222

See the full list for Washington →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →